-
Posted by
Two Blokes Jul 13 -
Filed in
Stock
-
4 views
Despite Trump's hot take toward the pharmaceutical industry and his hard stance on U.S. trading partners, Novartis' share price continues to rise. The main contributors to maintaining bullish sentiment towards the Swiss pharmaceutical behemoth are the strong performance of its cardiovascular, oncology, and immunology franchises. For example, sales of its blockbuster Cosentyx amounted to $1.53 billion in the first three months of 2025, up 15.7% year-on-year.
